cDNA fragments coding for the carboxy terminus of the El envelope glycoprotein from mouse hepatitis virus A59, a coronavirus, were cloned into the bacterial expression vector pEX. Clones expressing El antigenic determinants were selected with a polyclonal anti-El antibody and used for immunization of rabbits and for affinity purification of existing polyclonal antisera. Immunofluorescence testing and immunoperoxidase labeling of coronavirus-infected cells showed that these reagents were monospecific for El. In addition, by using hybrid proteins containing different lengths of the El carboxy terminus to affinity-purify a polyclonal antiserum against El, we have been able to define two epitopes within the last 15 amino acid residues of the protein. These epitope-specific antibodies bind to El in Golgi and perinuclear membranes as well as to budding viruses; they do not, however, label the plasma membrane or the membranes of post-Golgi vesicles transporting virions to the cell surface.
Several classes of enveloped RNA viruses bud at intracellular membranes rather than at the cell surface. One of the better characterized of these is the group of coronaviruses which initially bud into a smooth membrane compartment between the rough endoplasmic reticulum (RER) and the Golgi complex and later, during infection, into the cisternae of the RER (7, 20) . Progeny viruses are then transported across the Golgi cistemae and from there in large smooth membrane-bound vesicles to the plasma membrane. The virions are released into the medium by fusion of these vesicles with the plasma membrane (17) . tUnlike other enveloped viruses (e.g., Semliki Forest virus and vesicular stomatis virus) where viral glycoproteins accumulate at the cell surface, the newly synthesized coronavirus membrane glycoprotein El accumulates intraceilularly at the site of budding and determines the location of budding (20) . A similar intracellular localization of the El glycoprotein has been observed in cells transfected with the El gene (2) in a simian virus 40 vector (J. Armstrong and H. Nieman, personal communication). Therefore, the intracellular localization is likely to be a property of the El glycoprotein rather than an association with the other viral proteins. This apparent targeting of El to specific intracellular membranes makes it an interesting model with which to study the sorting of membrane proteins. In addition, the initial accumulation of El in a transitional vesicular compartment between the RER and the Golgi apparatus or in transitional elements of the RER (20) raises the possibility that this otherwise inaccessible compartment could be purified from coronavirusinfected cells if a specific antibody were available. As a first step toward this goal, we describe here the generation of specific antibodies which bind exclusively to the cytoplasmic tail of the viral protein.
MATERIALS AND METHODS
Cells and virus. Sac(-) cells (23) were grown as previously described (20) and seeded 24 h before use at a density of 2 x * Corresponding author.
106 cells per ml onto glass cover slips (24 mm x 24 mm) for immunofluorescence testing and into 35-mm round dishes (Nunc A/S, Roskilde, Denmark) for immunoperoxidase labeling. The cells were routinely infected at 100 PFU per cell with mouse hepatitis virus A59 (MHV-A59) (original virus stock from B. van der Zeijst, Utrecht, The Netherlands). The virus was propagated in sac(-) cells as previously described (20) .
Expression of hybrid El-p-galactosidase proteins. pEX recombinants in an Escherichia coli K-12 strain (15) containing coronavirus cDNA fragments were maintained at 30°C, and hybrid proteins were produced by shifting logarithmically growing cells to 42°C for 1 h (14, 15) .
The size of the El fragments in the larger hybrid proteins was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and restriction digestions (see below). The length of the three smallest inserts was verified by nucleotide sequence analysis after subcloning into M13mp8RF and sequencing by the Sanger method (13) .
SDS-PAGE of the hybrid proteins and the El glycoprotein. Analysis of the bacterial cultures was performed by using 7.5% polyacrylamide gels as previously described (9, 24) , and the resolved proteins were identified by silver nitrate staining (1). 10 ,ug/ml in TN-BSA plus 0.1% Triton X-100. After a thorough wash in TN-BSA plus 0.1% Triton X-100, the bound antibody was detected by using 125I-protein A (200,000 cpm/ml) in TN-BSA plus 0.1% Triton X-100. The filters were then washed well in TN plus 0.1% Triton X-100, dried, and counted.
Immunoblotting. The resolved bacterial proteins or the TX114 solubilized El protein, or both, were transferred to nitrocellulose as described by Burnette (6) . The (19) and conjugated to rhodamine.
Immunoperoxidase labeling. Immunoperoxidase labeling was performed as described previously (10, 21) by using as the first antibody either 4-017-ml, the RaEl antibody, or two polyclonal antibodies raised against the hybrid proteins H15 and H97 which were designated RaH15 and RaH97, respectively. The second antibody was a peroxidase-conjugated Construction of pCVE1 clones. Fragments from the 3' end of the El gene, generated by a BAL 31 resection, were cloned into pEX1-3. Seven fragments of different sizes are illustrated, and the hybrid proteins which they code for are noted under each. One hybrid protein, H161, which codes for 161 amino acids of El, extends into the membrane-spanning region (3I). The scale indicates the base pairs of the clone of the El gene (2) that was used. PR, promoter from bacteriophage X; cro, cro gene; Tfd, transcription terminator from phage fd.
sheep anti-mouse or goat anti-rabbit antibody F(ab')2 (Cooper Biomedical, Inc., West Chester, Pa.). After the reaction, the cell monolayers were dehydrated with ethanol, removed from the dish with propylene oxide, and embedded in Epon 812.
RESULTS
Construction of pCVEl clones. Small 3' fragments of the El gene were generated by a BAL 31 resection from a PstI site at the 5' end of the gene cloned in plasmid p8E1 (kindly given by J. Armstrong) followed by BamHI digestion (Fig.  1) . The fragments, which included the termination codon of El, were size fractionated on an agarose gel and ligated into a mixture of pEX1-3 cut with SmaI and BamHI. Competent cells of a strain containing the cIts857 repressor were transformed with this DNA, and recombinant plasmids were selected on ampicillin plates at 30°C. Plasmids were prepared from 96 of these colonies, and the sizes of El DNA inserts were measured by restriction enzyme digests. Thirtythree clones containing inserts of 320 base pairs or less were then screened for correct translational reading frame fusions by measuring the hybrid proteins by SDS-PAGE and by measuring immmunoreactivity toward the polyclonal antiserum (RaEl). A total of 12 of the 33 clones had in-frame fusions in agreement with the theoretical figure of 1 in 3. Of these, nine were identified by the size of the open reading frame on SDS-PAGE, but the smallest clones Hll, H15, H25, and H31 were identified only by immunoreactivity tests (Fig. 2, lanes 1, 2, 4 , and 5). Interestingly, the two smallest El inserts, which were shown by nucleotide sequence analysis to code for only 11 and 15 amino acids of the carboxy terminus of El, appeared to bind RaEl antiserum as strongly as any of the longer hybrids. It was immediately apparent, therefore, that one or more antigenic sites of the El protein were present at the carboxy terminus of El which is found on the cytoplasmic side of RER membranes (11, 12) . We therefore asked whether the carboxy terminus of El was the only immunogenic region in the TX114-extracted protein and attempted to produce carboxy-terminal-specific antibodies by both affinity purification of RaEl sera on the hybrid proteins and by raising antibodies to hybrid proteins in rabbits.
Antigenic structure of coronavirus glycoprotein El. The antigenic structure of the coronavirus glycoprotein El after VOL. 60, 1986 on July 7, 2017 by guest http://jvi.asm.org/ Downloaded from TX114 extraction of solubilized infected cell extracts and virions was determined by adsorption of the RcEl serum with saturating amounts of hybrid proteins bound to nitrocellulose paper (Fig. 3) . The antibody remaining in the unbound fraction and that eluted at a low pH from the nitrocellulose paper were assayed by indirect immunofluorescence labeling of infected cells (see Fig. 4) ) and by immunoblotting (see Fig. 5 ).
After affinity purification of RcxEl on H161, a hybrid protein containing the entire cytoplasmic domain of El, an antibody (RcxEl/161) was derived from the RaEl antiserum which showed a perinuclear labeling in immunofluorescence microscopy of coronavirus-infected cells similar to that obtained with the original antiserum ( Fig. 4A and B) but lacking the diffuse cytoplasmic stain associated with the crude antiserum, which is probably owing to antibodies raised against the viral core protein (N). Conversely, the unbound fraction remaining after adsorption with saturating amounts of H161, termed RoEl-161, showed a diffuse label in infected cells, most likely owing to remaining antibodies against N, and did not bind to El on immunoblots (data not shown). This establishes that in the RaEl antiserum the principal immunogenic region of the El molecule solubilized in TX114 is located in the carboxy-terminal region. Further adsorption of RcEl/161 (or the original serum) with hybrid protein 11 yielded two fractions, an affinity-purified antibody eluted from the nitrocellulose filter (RaxEl/161/11) and an unbound fraction (RoxEl/161-11). The antibody affinity purified on hybrid protein 11 (RaEl/161/11) was capable of binding strongly to hybrids of all lengths (Fig. 5, panel A This antibody also showed perinuclear labeling by immunofluorescence which was indistinguishable from that of RcxEl/161 ( Fig. 4B and C) . The unbound fraction RoxEl/161-11 no longer bound to hybrid protein 11 on immunoblots, as was expected (Fig. SB, lane 1) . It had, however, a significant reaction with all hybrids containing larger El fragments (Fig. SB, lanes 2 to 8) . This antiserum also labeled by indirect immunofluorescence a perinuclear region in infected cells (Fig. 4D) SC), although binding activity to all hybrid proteins containing 15 amino acids or more of El was still present in the antibody (RaEl/161-11/15) eluted off the filter (data not shown). Identical results were obtained by using H97 as the primary immunoadsorbent and the same protocol (data not shown). These results are most simply interpreted by the presence of two epitopes at the carboxy terminus of El, one in the last 11 amino acids, and one located principally between the 11th and 15th residues from the carboxyterminal end. Furthermore, virtually all antibody molecules in the RaEl antiserum must be directed against one or the other of these epitopes since no El-binding activity was observed after adsorption with hybrid protein 15 (Fig. SC) .
The presence of two epitopes in the 15 carboxy-terminal amino acids of El was confirmed by dot blots with RotEl and (Fig. 6A ). In the absence of detergent, no fluorescent labeling was observed with RaEl (data not shown), confirming that the antigenic sites recognized by RaEl are not located on the amino terminal portion of El which is found on the external surface of virus particles. This result was confirmed by electron microscopy after immunoperoxidase labeling with the antiserum (see below), which clearly indicates that the RaEl antibody recognizes only portions of the El molecules on the cytoplasmic side of intracellular membranes.
Raising antibodies to the carboxy-terminal domain of El. Six hybrid proteins, containing 97, 83, 31, 25, 15, and 11 amino acids of El, were used to immunize rabbits. Sera were screened for anti-El antibodies by indirect immunofluorescence in permeabilized infected cells. Antisera against three hybrid proteins, H15, H25, and H97, labeled El as determined by the characteristic strong perinuclear fluorescence Coronavirus-infected sac(-) cells were prepared as described in the legend to Fig. 3 (Fig. 6B) . The remaining three proteins, H31, H83, and, interestingly, Hll, did not generate any El-specific antibodies detectable by immunofluorescence. There was no correlation between the size of the hybrid protein and the immune response. All six antisera did, however, react by immunoblotting with the hybrid proteins which had been used as antigens, indicating that there had been an immune response to at least the cro-lacZ portion in all cases (data not shown).
The positive antisera RaH15, RaoH25, and RaH97 were characterized by immunocytochemical techniques. By indirect immunofluorescence testing, the perinuclear intracellular labeling pattern they gave on MHV-A59-infected sac(-) cells was indistinguishable from that obtained with the RaEl antiserum and the monoclonal anti-El antibody (cf. Fig. 6A and B). However, at the electron microscopic level after immunoperoxidase labeling, a striking difference was observed. With the monoclonal antibody MaEl (Fig. 7A ) the lumenal faces of well-preserved Golgi cisternae were heavily labeled, as were the outer surfaces of budding and mature virions. By contrast, with the antiserum raised against H97, RaH97 (Fig.  7B) , the cytoplasmic face of the perinuclear membranes was labeled. This shows that the antiserum to H97 contains antibodies directed against the cytoplasmic domain of El. The morphological preservation of intracellular membranebound compartments after immunoperoxidase labeling was very poor when either the antiserum to hybrid protein H97 (Fig. 7B) or the antiserum to hybrid protein H15 and the polyclonal antiserum RacEl was used (data not shown). However, no destruction of form was observed under identical conditions of fixation and reaction when the polyclonal RaEl antiserum was affinity purified on H15 immobilized on a glutaraldehyde-activated matrix to obtain an anti-peptide antibody (RtEl/15) with the same specificity as the antibody raised against hybrid protein H15, RaH15 (Fig. 7C) . The cytoplasmic face of peri-Golgi membranes and Golgi cisternae as well as partially budded virions were heavily labeled. The labeling of partially budded virions is most likely owing to the reaction of RaEl/15 with El molecules not yet complexed with the viral ribonucleoprotein core and the subsequent diffusion of the reaction product in the region where the bud formed. The cytoplasmic face of post-Golgi compartments and the fully budded virus particles in the lumens of these compartments were not labeled.
These results confirmed the conclusion reached from these and other experiments involving trypsin digestion of intact virions followed by dot blotting (S. Tooze, unpublished results), which indicated that the monoclonal antibody recognizes the lumenal N-terminal domain of El, whereas the polyclonal antiserum RaEl and the antibodies against the hybrid proteins bind only to the cytoplasmic carboxyterminal domain of El. In virions, the cytoplasmic domain might not be accessible to antibodies specific for the 15 carboxy-terminal amino acids even after detergent treatment, or it could be complexed with the viral ribonucleoprotein core, which would inhibit binding of the antibody to the carboxy-terminal domain.
DISCUSSION
Coronavirus El transmembrane glycoprotein is cotranslationally inserted into the RER such that its amino terminus is exposed on the lumenal side of the membrane and the carboxy-terminal region of the protein is accessible from the cytoplasmic faces of intracellular membranes (11) . A suitable immunological reagent for detecting El in intra- By using a polyclonal antibody against the hybrid protein H97, labeling is restricted to the Golgi region. However, the forms of the Golgi cisternae were not well preserved when this antibody and also the antibody to hybrid protein H15 (data not shown) were used. In contrast, (C) the cytoplasmic faces of perinuclear and Golgi membranes are labeled by the affinity-purified antibody RaEl/15. Note that whereas budding virions (p) are labeled, mature virions are not labeled either in the cistemae of the Golgi apparatus (-) or in the post-Golgi vesicles (V). Also note in panels B and C that neither the lumenal nor cytoplasmic faces of the RER are labeled. In addition, in panel C the membranes of post-Golgi vesicles (V) which transport virions are not labeled. Bars, 0.25 pLm. cellular membranes or for immunoaffinity purifications of membranes containing El must be capable of binding to the carboxy-terminal region of El. In this respect complete virus particles are unsuitable as antigens because in the virion the carboxy-terminal domain of El is probably complexed with the viral nucleocapsid (16) and only the amino terminal domain is exposed on the outside of the viral envelope. This is a consequence of the mode of budding of the virions. Nucleocapsid threads in the cytoplasm associate with the carboxy-terminal domain of El inserted in intracellular membranes, and the virion buds into the lumen of the intracellular compartment. As a result, only the amino terminal domain is exposed on the particle. Therefore, to raise antibodies specific to the carboxyterminal domain of El, we took a recombinant DNA approach in which ,B-galactosidase-El hybrid proteins were used either to affinity purify existing polyclonal sera or to immunize rabbits directly. This strategy has several advantages. First, the size of the El fragment can be manipulated by selection of appropriate cDNA clones. Not only are the antibodies produced of predetermined specificity, but they J. VIROL.
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.tN on July 7, 2017 by guest http://jvi.asm.org/ Downloaded from can also be selected to correspond either to short consecutive epitopes on the surface of the protein or to longer domains of the molecule to optimize binding in vivo or to neutralize a specific function. Second, the hybrid proteins produced in E. coli cannot be contaminated with other viral proteins as occurs in any biochemical purification. This means that the antibodies produced are monospecific for El, as was shown by immunofluorescence and immunoperoxidase labeling with antibodies raised to H15 and H97. We chose to use this approach rather than generating an antipeptide antibody for two reasons. First, the El gene was available as was the methodology for generating hybrid proteins. Second, because the disposition of the carboxyterminal region of El in the membrane was not clear (2), we thought to optimize our chances of obtaining a good antibody reagent by using various lengths of the carboxyterminal domain, instead of a peptide of a defined size.
In vitro assembly experiments (11) have shown that after El is inserted into dog pancreas microsomal membranes most of the protein is inaccessible to proteolytic enzymes. On the cytoplasmic side of the membrane, a fragment of 1.5 kilodaltons can be removed with proteinase K. This fragment corresponds to the 15 carboxy-terminal amino acids which we have shown contain all the major immunogenic sites of the El protein generated from a TX114 extract. It is very likely, therefore, that this region is highly accessible in the detergent-purified protein which is assumed to be in a native structure (5) . In addition, according to a recent sequence analysis study comparing El glycoproteins of infectious bronchitis virus and MHV-A59 (12), it is likely that only about the last 10 amino acids of El are exposed on the cytoplasmic face of the membrane. It is probable that the immunogenicity of this region is a result of its accessibility (4, 18, 22) .
The carboxy-terminal domain of El is interesting with respect to strain divergence and viral maturation. Two isolates of MHV-A59 were used in these studies. The amino acid sequences of the El glycoprotein from these two isolates differ in the last carboxy-terminal amino acid. One isolate from Utrecht contains a threonine residue, the other from Giessen contains an isoleucine residue (J. Armstrong and H. Niemann, personal communication). All of the biochemical and immunological characterization was done by using the virus strain from Utrecht, whereas the cDNA used to construct the hybrid proteins was from the Giessen strain. We could detect no differences in reactivity of the RaH15 serum or RaH97 serum by immunofluorescence labeling or by immunoblotting (data not shown) with either strain, which suggests that this mutation is immunologically silent.
The antibodies we generated clearly reveal the intracellular location of El. The pattern of immunoperoxidase labeling (Fig. 7) obtained with RaH97 and RotEl/15 is significant. In infected cells, the cytoplasmic faces of peri-Golgi and Golgi membranes are heavily labeled. But the membranes of post-Golgi vacuoles carrying progeny virions from the Golgi apparatus to the cell surface are unlabeled, as is the plasma membrane. This proves at the level of resolution of the electron microscope that El is not transported as a transmembrane protein beyond the Golgi apparatus.
The antibodies described here recognize two epitopes within the 15 carboxy-terminal amino acids of El which are accessible from the cytoplasmic faces of intracellular membranes containing El but are inaccessible in intact virions. The antibodies raised against or affinity purified with the hybrid proteins containing these epitopes will be used with immunoaffinity techniques to isolate the intracellular membrane compartments in which El accumulates.
